19hon MSN
Q4 2024 Management View CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...
Key Takeaways AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat ...
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
24/7 Wall St. on MSN18h
AbbVie (ABBV) Earnings Live: Why The Stock Is Up Big TodayLive Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 11:53 am Looking ...
8don MSN
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...
AbbVie Inc (ABBV) surpasses revenue expectations with robust performance in immunology and neuroscience, while navigating challenges in aesthetics and biosimilar competition.
(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback